Key Takeaways Lilly's oncology sales hit 4.4BinH12025,up104.4B in H1 2025, up 10% and constituting about 15% of total revenues.Portfolio spans older drugs like Alimta and Erbitux to newer assets, Jaypirca and Retevmo.Imlunestrant, under review in the U.S. and EU, could soon expand Lilly's oncology growth drivers.Eli Lilly’s (LLY) extraordinary revenue expansion remains anchored in its cardiometabolic franchise, where blockbuster GLP-1 drugs Mounjaro and Zepbound powered 4.4BinH12025,up1020.6 billion in sales during the first half of 2025, ...
礼来(US:LLY) ZACKS·2025-09-10 00:26